Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation
- 29 December 2009
- journal article
- research article
- Published by Proceedings of the National Academy of Sciences in Proceedings of the National Academy of Sciences of the United States of America
- Vol. 107 (1), 407-412
- https://doi.org/10.1073/pnas.0902006107
Abstract
Fibroblast growth factor (FGF) 23 inhibits renal phosphate reabsorption by activating FGF receptor (FGFR) 1c in a Klotho-dependent fashion. The phosphaturic activity of FGF23 is abrogated by proteolytic cleavage at the RXXR motif that lies at the boundary between the FGF core homology domain and the 72-residue-long C-terminal tail of FGF23. Here, we show that the soluble ectodomains of FGFR1c and Klotho are sufficient to form a ternary complex with FGF23 in vitro. The C-terminal tail of FGF23 mediates binding of FGF23 to a de novo site generated at the composite FGFR1c-Klotho interface. Consistent with this finding, the isolated 72-residue-long C-terminal tail of FGF23 impairs FGF23 signaling by competing with full-length ligand for binding to the binary FGFR-Klotho complex. Injection of the FGF23 C-terminal tail peptide into healthy rats inhibits renal phosphate excretion and induces hyperphosphatemia. In a mouse model of renal phosphate wasting attributable to high FGF23, the FGF23 C-terminal peptide reduces phosphate excretion, leading to an increase in serum phosphate concentration. Our data indicate that proteolytic cleavage at the RXXR motif abrogates FGF23 activity by a dual mechanism: by removing the binding site for the binary FGFR-Klotho complex that resides in the C-terminal region of FGF23, and by generating an endogenous inhibitor of FGF23. We propose that peptides derived from the C-terminal tail of FGF23 or peptidomimetics and small-molecule organomimetics of the C-terminal tail can be used as therapeutics to treat renal phosphate wasting.Keywords
This publication has 51 references indexed in Scilit:
- Inactivation of klotho function induces hyperphosphatemia even in presence of high serum fibroblast growth factor 23 levels in a genetically engineered hypophosphatemic ( Hyp ) mouse modelThe FASEB Journal, 2009
- FGF23 Elevation and Hypophosphatemia after Intravenous Iron Polymaltose: A Prospective StudyJournal of Clinical Endocrinology & Metabolism, 2009
- Initial FGF23-Mediated Signaling Occurs in the Distal Convoluted TubuleJournal of the American Society of Nephrology, 2009
- Molecular genetic and biochemical analyses of FGF23 mutations in familial tumoral calcinosisAmerican Journal of Physiology-Endocrinology and Metabolism, 2008
- Calcimimetics as an Adjuvant Treatment for Familial Hypophosphatemic RicketsClinical Journal of the American Society of Nephrology, 2008
- Molecular Insights into the Klotho-Dependent, Endocrine Mode of Action of Fibroblast Growth Factor 19 Subfamily MembersMolecular and Cellular Biology, 2007
- Klotho converts canonical FGF receptor into a specific receptor for FGF23Nature, 2006
- Suppression of Aging in Mice by the Hormone KlothoScience, 2005
- Establishment of the Anti-Klotho Monoclonal Antibodies and Detection of Klotho Protein in KidneysBiochemical and Biophysical Research Communications, 2000
- Pex Gene Deletions in Gy and Hyp Mice Provide Mouse Models for X-Linked HypophosphatemiaHuman Molecular Genetics, 1997